Targeting Beta-Blocker Drug–Drug Interactions with Fibrinogen Blood Plasma Protein: A Computational and Experimental Study

Abstract

In this work, one of the most prevalent polypharmacology drug–drug interaction events that occurs between two widely used beta-blocker drugs—i.e., acebutolol and propranolol—with the most abundant blood plasma fibrinogen protein was evaluated. Towards that end, molecular docking and Density Functional Theory (DFT) calculations were used as complementary tools. A fibrinogen crystallographic validation for the three best ranked binding-sites shows 100% of conformationally favored residues with total absence of restricted flexibility. From those three sites, results on both the binding-site druggability and ligand transport analysis-based free energy trajectories pointed out the most preferred biophysical environment site for drug–drug interactions. Furthermore, the total affinity for the stabilization of the drug–drug complexes was mostly influenced by steric energy contributions, based mainly on multiple hydrophobic contacts with critical residues (THR22: P and SER50: Q) in such best-ranked site. Additionally, the DFT calculations revealed that the beta-blocker drug–drug complexes have a spontaneous thermodynamic stabilization following the same affinity order obtained in the docking simulations, without covalent-bond formation between both interacting beta-blockers in the best-ranked site. Lastly, experimental ultrasound density and velocity measurements were performed and allowed us to validate and corroborate the computational obtained results.

COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning

“…Thus, polypharmacological therapies are arguably more efficient by targeting multiple disease-associated viral genes ( Paolini et al, 2006 ; Apsel et al, 2008 ; Hopkins, 2008 ; Hopkins, 2009 ). Identifying proper target combinations and designing effective multi-targeting agents require approaches such as in silico drug design, which provides a powerful tool to speed up chemical compound screening ( Chaudhari et al, 2017 ; Peng et al, 2018 ; Balasubramaniam and Reis, 2020 ; González-Durruthy et al, 2020 ).…”

Elevated Fibrinogen Level Reduces Therapeutic Efficiency of AD Drugs: Biophysical Insights into the Interaction of FDA-Approved Cholinesterase Inhibitors with Human Fibrinogen

“…From the structural point of view, the entire length of the FIB molecule can be divided into three major portions (Figure S1), of which the N-terminal central region is called the E-region, which is found to be the most favorable pocket for ligand binding. − The main funnel hydrophobic cavity (called pocket 1) is the main binding site of the E-region, corresponding to the thrombin-binding domain. , All the drugs bind within the multiple cavities densely located in the N-terminal central nodule E-region. In general, this suggests that the interactions (Table S1) fit with a spontaneous thermodynamic process, as indeed manifested in the negative Δ G values.…”

A novel insight into mechanism of derangement of coagulation balance: interactions of quantum dots with coagulation-related proteins

“…FIB is a soluble glycoprotein composed by disulfidelinked dimer of three nonidentical polypeptide chains, Aα, Bβ, and γ [52]. Previous results showed that multiple cavities more densely located in the N-terminal central nodule E-region of FIB corresponded to the thrombin binding-domain, which have critical importance for the blood coagulation process [53]. Therefore, the molecular docking simulations focused on the potential docking interaction between L-GSH and L-Cys with E-region of FIB.…”